Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2019 07:30 ET | Source: OpGen, Inc.

OpGen to Present on Guiding Precision Antibiotic Therapy with Rapid Genomics and Informatics at IDWeek 2019

GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that data from its Acuitas AMR Gene Panel and Acuitas Lighthouse Software will be presented during...
September 18, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Provides update on Curetis Group’s R&D Collaboration

Curetis R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbCollaborator to fund R&D and obtains option to license ARESdb and ARES Technology...
September 04, 2019 06:55 ET | Source: OpGen, Inc.

Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses

Combined company creates a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for molecular microbiologyCombined company to be headquartered in Gaithersburg, MD,...
August 07, 2019 16:05 ET | Source: OpGen, Inc.

OpGen Reports Second Quarter 2019 Financial Results and Provides Business Update

Revenue up 28% Quarter-over-Quarter Progression of 510(k) submission to the FDA for clearance of the Acuitas® AMR Gene Panel test for bacterial isolates Conference call to be held at 4:30 p.m....
July 30, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Announces Date of Second Quarter 2019 Financial Results Conference Call

GAITHERSBURG, Md., July 30, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its second quarter 2019 financial results after the close of the U.S....
June 27, 2019 07:30 ET | Source: OpGen, Inc.

OpGen’s Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy

Collaborator data demonstrating OpGen’s rapid prediction of antibiotic resistance and detection of uropathogens presented at ASM Microbe 2019 GAITHERSBURG, Md., June 27, 2019 (GLOBE NEWSWIRE) --...
June 13, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Announces New Data Demonstrating Clinical Utility for Antibiotic Resistant Urinary Tract Infection Patient Management and for Rapid Carbapenem-Resistant Bacteria Outbreak Detection

GAITHERSBURG, Md., June 13, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that data from its Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software will be presented at ASM...
May 14, 2019 16:01 ET | Source: OpGen, Inc.

OpGen Reports First Quarter 2019 Financial Results and Provides Business Update

Submission of 510(k) application to the FDA for clearance of the Acuitas® AMR Gene Panel test for bacterial isolates Revenue up 21% Quarter-over-Quarter Conference call to be held at 4:30 p.m....
May 14, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Completes Initial FDA 510(k) Submission for its Acuitas® AMR Gene Panel Test to Identify Presence of Antibiotic Resistance

GAITHERSBURG, Md., May 14, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that it has filed its 510(k) submission with the U.S. Food and Drug Administration (FDA) for clearance...
May 07, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Announces Date of First Quarter 2019 Financial Results Conference Call

GAITHERSBURG, Md., May 07, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its first quarter 2019 financial results after the close of the U.S....